Condition: Alzheimer Disease · Alzheimer Disease, Early Onset · Sponsor: Arrowhead Pharmaceuticals
Study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics of ARO-MAPT-SC compared to placebo in adult healthy volunteers and in participants with early Alzheimer's disease (AD), defined as mild cognitive impairment due to AD and mild AD dementia.
This description comes directly from the study's public registry record.
Medical Monitor · 626-304-3400 · AROMAPT-SC-1001@arrowheadpharma.com
Always discuss trial participation with your own doctor first.
| Research Site 3 | East York, Ontario, Canada | Recruiting |
| Research Site 2 | Toronto, Ontario, Canada | Recruiting |
| Research Site 1 | Grafton, Auckland, New Zealand | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07221344